sch 717454 in subjects with relapsed osteosarcoma or ewing’s sarcoma protocol p04720
DESCRIPTION
SCH 717454 in Subjects with Relapsed Osteosarcoma or Ewing’s Sarcoma Protocol P04720. CTOS Nov 2008. Disclosure. Neither I , nor my colleagues have any stock nor have we been paid consultants of Schering-Plough Investigators have received research funds for this study (P04720). - PowerPoint PPT PresentationTRANSCRIPT
SCH 717454 in Subjects with Relapsed
Osteosarcoma or Ewing’s Sarcoma
Protocol P04720
CTOS Nov 2008
2
Disclosure
• Neither I , nor my colleagues have any stock nor have we been paid consultants of Schering-Plough
• Investigators have received research funds for this study (P04720).
3
Insulin Growth Factor Pathway
IGF-II/IGF-I
IGF-1R
PP
PERK1/2
AKT
4
SCH 717454: A Potent & Specific anti-IGF-1R Monoclonal Antibody
High Affinity Fully Human IgG1 clone 19D12
Does Not Recognize Insulin Receptor
Properties and Activities That May Contribute To Antitumor Effects:
• Inhibits IGF ligand binding and IGF-1R signaling• Downregulation of IGF-1R protein level• Antibody-dependent cellular cytotoxicity• Enhances other agents in pre-clinical studies
IGF-1R IGF-1R/IR
dimer
InsulinReceptor
(IR)
5
SCH717454 & Osteosarcoma Xenografts
• Inhibits osteosarcoma, Ewing’s sarcoma & neuroblastoma xenografts
• Pediatric preclinical testing program: complete responses in 2 out of 6 osteosarcoma (OS1, OS9) & 1 Ewing’s sarcoma cell line (EW5). Improved Event Free survival in 4/6 osteosarcoma and 2/5 Ewing’s models.
•Kolb, Gorlick et al. 2008
SCH 717454 Inhibits SJSA-1 Growth in vivo
Staged model, 2 x weekly
SCH 717454 Causes Regression of OS-1 in vivo (PPTP / NCI)
1 2 3 4 5 60
4.0
3.0
2.0
1.0
0.0
Treatment
Control
Rel
ativ
e Tu
mor
Vol
ume
Time (weeks)
0
250
500
750
1000
1250
1500
1750
2000
0 2 4 6 8 10 12 14 16 18 20 22 24
Days (post dosing)
Tum
or S
ize
(mm
3 )
Vehicle Control 0.02 mg SCH 7174540.1 mg SCH 7174540.5 mg SCH 717454
Staged model, starting tumor volume: 250 mm3, 0.5 mg SCH 717454, 2 x weekly
6
Endpoints Primary: Response Secondary: TTP, Safety, PK, PD
Recurrent/refractoryOsteosarcoma or Ewing’s Sarcoma(N25-50 each)
SCH 717454 10 mg/kgQ 2 weeks
Refractory Osteosarcoma or Ewing’s Sarcoma Cohorts
7
Key Inclusion/Exclusion Criteria
• Key Inclusions– ≥11 years of age – Osteosarcoma or Ewing’s sarcoma
• Key Exclusions– Diabetics: hemoglobin A1C >7.5% – Heart disease, hepatitis or active infection– Prior anti-IGF-1R drug
8
Serum IGF-1 Concentrations During Treatment
0
100
200
300
400
500
600
700
Baseline 2 wks after Single Dose (Trough Level)
SubsequentDoses (at Trough)
IGF-
1 bl
ood
leve
l (ng
/ml)
9
IGF-1R Occupancy On Peripheral Blood Mononuclear Cells
0
10
20
30
40
50
60
Baseline Two Weeks Post-Dose (Obtained at Trough)
% o
f IG
F-1R
un-
occu
pied Flow cytometry
assay measuring the percent of cells that bind labeled SCH
717454at baseline (blue)
versus2 weeks post single dose of
SCH 717454 (purple)
10
Preliminary Response Data
• Osteosarcoma: stable disease in >5* (1 stable to >6 months; another ongoing response with both lung and bone metastases)
• Ewings: 3 PRs; some of subjects with mixed responses
*Initial data on subject at 8 weeks on study
11
Preliminary Ewing’s Response
Before After Single Dose
11 year old female with recurrent/refractory Ewing’s Sarcoma s/p 3 prior therapies
12
Responding Ewing’s Sarcoma
Before After (8 weeks)
29 year old male with recurrent/refractory Ewing’s Sarcoma s/p 3 prior therapies
13
Near Complete Response in Ewing’s
Before at 8 week assessment
28 year old male with recurrent/refractory Ewing’s Sarcoma s/p 2 prior therapies
14
Most Common Adverse Events
Adverse EventIncidence
Grade 1 Grade 2 Grade 3 Grade 4
Headache 5 (8%) 1 (2%) 0 0
Fatigue 1 (2%) 3 (5%) 0 0
Hyperglycemia 3 (5%) 0 1 (2%) 0
Pruritus 3 (5%) 1 (2%) 0 0
Nausea 3 (5%) 1 (2%) 0 0
Back Pain 0 0 3 (5%) 0
Constipation 1 (2%) 1 (2%) 1 (2%) 0
Dyspnoea 1 (2%) 1 (2%) 1 (2%) 0
Pneumothorax 2 (3%) 0 1 (2%) 0
15
Safety/Tolerability Summary
• Well tolerated– Most AEs mild or moderate
• Hyperglycemia– Generally mild if present
– Only 1 moderate/severe event in an adult diabetic
– No severe or life-threatening drug-related AEs
16
P04720: Group 1
Recurrence
TTP
ResectableDisease
SCH 717454 Dose Level
1Prior
Surgery
Recurrence
Surgery
SCH 717454 Dose Level 2
Tumor Proliferation
Tumor Proliferation
TTP
SCH 717454 Dose Level
1
SCH 717454 Dose Level
2
Primary Endpoint: tumor proliferation Secondary Endpoint: TTP/Time to relapse
17
Summary
• Potent in preclinical models
• Clinically well-tolerated– Hyperglycemia uncommon, mostly mild
• Clinically active in Ewing’s sarcoma
• Stable disease in Osteosarcoma
• Enrollment continuing- North America, Europe, and South America
18
Acknowledgements
• Contributing Investigators – Drs. Anderson, Skubitz, Miller, Meyer, Arico, Mita,
Chawla, Katzenstein, O’Day, Desai, Villarroel, Lopez, Van de Graaf, Mas, Sandoval, Marec-Berard, Jean-Gentet, Bielack, and Klingelbiel
• Schering Plough Personnel– Drs. Lu, and Wang; Ms. Whitman
• All the patients and their families
• ? Questions?